EndoSphere has announced it has received a U.S. patent for endoscopically implantable devices for the treatment of metabolic diseases such as obesity and type 2 diabetes.
EndoSphere's inventions provide less invasive, safer and more physiologic treatment for obesity, according to a release from EndoSphere.
The company said obesity is its primary target. EndoSphere develops and commercializes devices such as the SatiSphere duodenal insert.
Read the release on the patient for EndoSphere
Related Articles on Procedures for Obesity:
Top 6 Risk Factors for Weight-Loss Surgery
Allergan Asks FDA to Approve Lap-Band Surgery for Teenagers
Obese Patients at Increased Risk of Surgical Infection After Colectomy